Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield NM drug list Coverage | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - New MexicoPolicy N/A

    2026 Drug List (pharmacy drug formulary) - Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - New Mexico policy alerts

    Know when Blue Cross Blue Shield - New Mexico releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    The document lists covered prescription and specialty drugs, coverage rules (e.g., tiers, prior authorization, step therapy, quantity limits), and member/provider guidance for Blue Cross Blue Shield of New Mexico pharmacy benefits; it is intended for members, prescribers, and pharmacists.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2026 Drug List (pharmacy drug formulary) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeMinor / No material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests and required clinical documentation when 'PA' is listed for a drug to obtain coverage before dispensing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~120drug/formulation lines in excerpt
    PA / QL / SPentries with utilization controls
    6member payment tiers
    Accredospecialty pharmacy vendor highlighted

    Pharmacy Coverage Criteria

    Pharmacy Coverage Overview

    Covered drugs are those listed on the Drug List and are governed by plan-specific rules; drugs not on the list are not covered.

    General Coverage Conditions: Drug must appear on the BCBSNM Drug List and be covered under the member's specific benefit plan; coverage may be limited by FDA labeling, evidence-based guidelines, or plan exclusions.

    From general introduction and coverage considerations

    Special requirements that may apply: Prior Authorization (PA), Step Therapy (ST), Dispensing/Quantity Limits (QL/DL), or Administrative/Behavioral Health/Not Medically Necessary (AC/BH/NM) designations may apply to specific drugs as noted on the Drug List.

    Special Requirements column annotations (PA, ST, QL, AC, BH, NM)

    Per-product coverage flags

    Coverage and utilization controls are specified per drug entry using Requirements/Limits flags (PA, QL, SP, AC, NM).

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2026 Drug List (pharmacy drug formulary) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeMinor / No material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests and required clinical documentation when 'PA' is listed for a drug to obtain coverage before dispensing.
    SourceLink
    On This Page
    Pharmacy Coverage CriteriaDrug List Coding and TiersProvider Requirements and Authorization ActionsDefinitions and Code FlagsInitial Dispensing and Therapy CriteriaStep Therapy / Fail-First RulesQuantity Limits and Maintenance Supply GuidanceSite-of-Care and Specialty PharmacyBackground
    Per-drug requirement flags: Each drug entry includes a Drug Tier and Requirements/Limits field. Flags include PA (prior authorization), QL (quantity limits with exact quantities/duration), SP (specialty pharmacy), AC (administrative condition), and NM (not medically necessary).

    No patient-level clinical criteria are provided in these chunks; only per-product controls are listed.

    General coverage controls

    Coverage and utilization management for listed drugs are governed by the following plan-level controls:

    Standard controls: If a drug entry lists 'PA' the plan requires prior authorization; if it lists 'QL' a specified quantity limit applies (examples in the Drug List include 'QL (30 tablets/30 days)', 'QL (180 tablets/30 days)', or specific mL limits); 'SP' indicates specialty product handling and possible specialty pharmacy dispensing.

    Applies per individual drug entry as specified in the Requirements/Limits field.

    Covered with product-specific PA/QL/SP

    Coverage entries with utilization controls are subject to specified PA and QL as listed per product.

    General coverage conditions: Coverage for a listed product is conditioned on meeting the line-item Requirements/Limits (e.g., obtaining PA where 'PA' is indicated and dispensing within the stated QL such as '1 pen/28 days' or '4 pens/28 days' for injectable pens). Specialty (SP) products may also require specialty pharmacy routing.

    Applies per individual product entries in this segment.

    Per-drug coverage conditions

    Drugs are listed with coverage-related flags; coverage requires meeting the listed flags per line (e.g., PA, QL, BH, SP).

    Per-drug requirement: Coverage for each listed drug formulation requires adherence to its listed Requirements/Limits (PA, QL, BH, SP) and placement on the formulary tier as shown.

    Providers must consult the specific line item for exact QL or PA requirements.

    Drugs must be listed on the BCBSNM Drug List to be covered. Drugs not shown on the list are not covered; repackaged versions, compounded medications (coverage depends on the member's plan), and non–FDA‑approved drugs are explicitly identified as not covered in the Coverage Considerations section. Providers and members should verify coverage and up‑to‑date formulary placement via bcbsnm.com, MyPrime.com, or the phone number on the member ID card.

    Within the provided extract there are no additional explicit exclusions stated beyond the general coverage limitations; the drug lines in this segment report tier and Requirements/Limits annotations without separate exclusion language.

    Several vaccine product lines are annotated with NM (Not Medically Necessary) alongside administrative codes (AC) in the Requirements/Limits field. These NM/AC annotations indicate that specific formulations, age groups, or indications may be considered not medically necessary or subject to administrative conditions

    Some drug entries are labeled as Non‑Preferred (np / NP) or otherwise tiered as non‑preferred. Where present, these annotations affect formulary status and member cost share; entries without PA or QL values are still shown but may be non‑preferred by tier. Providers should follow the Requirements/Limits flags (PA, QL, SP, AC, NM) shown on each product line when submitting claims or prior authorization requests.

    The lines in this segment provide drug name, tier and Requirements/Limits fields but do not include standalone clinical exclusion statements. Coverage is governed by the per‑product Requirements/Limits codes (e.g., PA, QL, SP, AC) shown for each line item.

    No explicit exclusion statements are present in the referenced chunks of the extract. The document in this area lists formulary lines and their tier/Requirements/Limits annotations without additional exclusion narrative.

    Certain product lines in the drug list are explicitly annotated with NM (Not Medically Necessary) for particular formulations — for example, multiple azithromycin and erythromycin entries in the macrolide section carry an NM flag (often paired with quantity limits). These NM annotations indicate that those specific formulations or uses are considered not medically necessary per the formulary listing and may be denied when billed for excluded indications.

    In the chunks referenced there are no explicit 'Not Medically Necessary' determinations beyond the previously noted examples; the entries here primarily present drug lines with tier and Requirements/Limits annotations.

    Multiple vaccine and biologic lines (e.g., COMIRNATY, SPIKEVAX, NUVAXOVID, ENGERIX‑B, PREVNAR 20) are annotated with AC and in some cases NM. Entries marked NM (for specific formulations, age ranges, or indications) indicate those product lines are regarded as not medically necessary in certain contexts and therefore excluded for those uses; providers should check the specific vaccine line and member benefit to determine allowable indications.

    No explicit Not Medically Necessary determinations are stated in these chunks. The extract largely lists formulary items and their flags; specific NM decisions appear where annotated on individual product lines elsewhere in the list.

    Drug List Coding and Tiers

    Drug list entries (no billing codes in these chunks)mixed
    N/ANDCs, CPT, or HCPCS codes are not present in these chunks; entries are drug name, strength, tier, and Requirements/Limits.
    Tier and Requirements annotationsmixed
    NPDrug Tier = NP (non-preferred or non-preferred specialty designation as listed)
    PDrug Tier = P (preferred)
    ACRequirements/Limits = AC (administrative condition / authorization code)
    NMRequirements/Limits = NM (not medically necessary for some indications)
    PARequirements/Limits = PA (prior authorization required)
    QLRequirements/Limits = QL (quantity limit with specifics following)
    SPRequirements/Limits = SP (specialty)
    Drug listing (no billing codes present)mixed
    NDCs not providedDocument lists drug names and formulations but does not list NDC or CPT/HCPCS/ICD-10 codes in these chunks.
    Quantity limit examples — common formats
    Example A30 tablets / 30 days
    Example B28 tablets / 28 days
    Example C60 tablets / 30 days
    Quantity limits — illustrative entries
    QL example 1QL (6 tablets / 180 days)
    QL example 2QL (120 capsules / 30 days)
    QL example 3QL (9 tablets / 30 days)
    QL example 4QL (126 tablets / 365 days)
    QL example 5QL (240 capsules / 30 days)
    Insulin quantity limit
    Insulin QL100 mls / 30 days
    Insulin example — FIASPQL (100 mls/30 days) listed for FIASP formulations
    Insulin example — HUMALOG/NOVOLOGMultiple rapid- and short-acting insulin products annotated QL (100 mls/30 days)
    Pen/pack limits for GLP‑1 and tirzepatide products
    Pen/pack example 11 pen / 28 days
    Pen/pack example 24 pens / 28 days
    Pen/pack example 34 pens / 180 days
    Tablet limits — examples
    Tablet limit — common short30 tablets / 30 days
    Tablet limit — extended60 tablets / 30 days or 60 tablets / 180 days as specified per product
    Product-specificExact tablet QL varies by product; see line item for 30 vs 60 tablet settings
    Quantity limits — assorted examples
    Capsule example30 capsules / 30 days
    Pen example1 pen / 28 days
    Oral solution example540 mls / 30 days
    Capsule example 260 capsules / 30 days
    Capsule example 3120 capsules / 30 days

    Provider Requirements and Authorization Actions

    Prior Authorization

    Prior Authorization Requirement

    Prior Authorization Required — Some medications listed in this formulary require prior authorization (PA). When a drug’s Requirements/Limits field includes “PA,” the prescriber must submit a prior authorization request and obtain approval before coverage will be allowed. Claims for PA‑listed products may be denied if PA is not obtained.

    • PA indicated in the Requirements/Limits column for many products (examples: EPCLUSA, HARVONI, SOVALDI, VOSEVI, VOSEVI).
    • Lack of PA may result in claim denial or delay.
    Prior Authorization

    Prior authorization required for selected specialty/high‑cost anti‑infectives

    Selected specialty or high‑cost anti‑infective agents and inhaled antibiotics require prior authorization and may have quantity limits and specialty pharmacy (SP) dispensing requirements. Examples include ARIKAYCE, TOBI formulations, KITABIS PAK, posaconazole formulations, and certain hepatitis C agents.

    • ARIKAYCE — PA, QL (28 vials/28 days), SP.
    • TOBI PODHALER / TOBRAMYCIN nebu soln — PA, QL, SP (examples: 280 mL/56 days or 224 capsules/56 days).
    • Posaconazole (NOXAFIL) formulations — PA for select formulations; some oral solutions have QL (1200 mL/30 days).
    Prior Authorization

    Prior authorization required for listed PA drugs

    Many individual branded or specialty drugs in the formulary are annotated with PA in the Requirements/Limits column; prescribers must submit PA requests per the plan’s submission process. Examples span oncology, specialty biologics, cardiometabolic agents, and other high‑cost brands.

    • Examples: numerous oncology/specialty agents (see oncology section) list PA + QL + SP flags.
    • Branded agents requiring PA include MYFEMBREE, ORIAHNN, MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY, and others.
    Prior Authorization

    Specialty program requirement for Palforzia

    Palforzia (peanut allergen powder) product lines are designated SP and have level‑specific packaging (initial dose, level packs, maintenance, titration). Specialty program workflows and specialty dispensing are likely required; prescribers should follow PA/Specialty pharmacy procedures when requesting coverage.

    • Palforzia levels and packs annotated with SP (specialty) — initial dose, levels 0–11, maintenance and titration packets.
    • Specialty authorization/workflow required for SP products; contact the number on the member ID card for PA or specialty routing.
    Prior Authorization

    Prior authorization required for many oncology/specialty drugs

    Prior authorization is required for many oncology and other specialty drugs. These products commonly carry PA plus quantity limits (QL) and SP flags; providers must submit documentation supporting diagnosis, prior therapies, dosing and intended duration to justify medical necessity.

    • Oncology examples with PA/QL/SP: ALUNBRIG, AYVAKIT, BALVERSA, BOSULIF, CABOMETYX, IBRANCE, IMBRUVICA, KISQALI, LYNPARZA, many others.
    • Submit PA with clinical rationale, relevant pathology/genetic tests, and prior treatment history when applicable.
    Prior Authorization

    Prior authorization required for selected branded agents

    Selected high‑cost branded agents require prior authorization prior to coverage. Examples in the formulary include MOUNJARO (tirzepatide), OZEMPIC (semaglutide), RYBELSUS, TRULICITY, and other GLP‑1 agonists and weight‑management or specialty endocrinology agents.

    • MOUNJARO — PA, QL (1–4 pens per period depending on strength).
    • OZEMPIC — PA, QL (1 pen/28 days).
    • RYBELSUS — PA, QL (30 tablets/30–180 days depending on strength).
    Prior Authorization

    Prior authorization required for selected agents

    Prior authorization is required for multiple GLP‑1 agonists and other specialty agents; submit PA requests per plan procedures to avoid denials.

    • MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY and other GLP‑1 agents are annotated PA and have QL entries.
    • Providers should include indication, prior therapies tried, and dosing plan in PA submissions.
    Prior Authorization

    PA for specialty/high‑cost drugs

    Many specialty or high‑cost products listed include PA and QL designations. For SP‑flagged products, specialty pharmacy dispensing and associated prior authorization workflows typically apply.

    • SP = specialty; claims may be routed to specialty pharmacies. Examples: EPCLUSA, HARVONI, SOVALDI, many oncology agents.
    • Ensure specialty pharmacy requirements are met (shipping, handling, administration settings) when submitting PA.
    Prior Authorization

    Prior authorization and quantity limits

    Prior authorization and quantity limits govern coverage — when a product lists PA and/or QL in Requirements/Limits, prescribers must obtain PA and adhere to the listed quantity limits. Exceeding QL or lacking PA may lead to denial or reduced benefits.

    • Quantity limit examples: QL 1 pen/28 days (OZEMPIC), QL 4 pens/28 days or 4 pens/180 days (MOUNJARO depending on strength), QL 6 syringes/28 days (REPATHA).
    • If dosing above the QL is medically necessary, include supporting documentation in the PA request.
    Prior Authorization

    PA required for listed specialty/high‑cost drugs

    Prior authorization is required for many listed specialty/high‑cost products across the formulary; check each drug entry’s Requirements/Limits for PA and QL notations and follow the specified submission process.

    • Examples: TREMFYA (PA, QL 1 syringe/28 days), VOWST (PA, QL 12 capsules/12 months), ZYMFENTRA products (PA, QL 2 pens/28 days).
    • Follow SP routing and PA submission steps for these products.
    Denial Risk

    NM flags may trigger denial

    NM (Not Medically Necessary) flags denote utilization constraints and may indicate that the product will be denied for the listed indication. Entries marked NM should trigger review of coverage criteria and, where appropriate, a PA or exception request with supporting clinical justification.

    • Examples: select azithromycin formulations annotated NM, many HIV/HCV products show NM for certain formulations.
    • NM annotation may indicate that the product is not covered for the billed indication and can trigger denial if billed without approved exception.
    Prior Authorization

    Prior authorization required for certain hepatitis agents

    Certain hepatitis C agents and other antiviral products are PA‑ and SP‑flagged due to high cost and specialized treatment regimens. Examples include EPCLUSA, HARVONI, SOVALDI, VOSEVI and related pellet or pack formulations — PA and QL apply.

    • EPCLUSA, HARVONI, SOVALDI, VOSEVI — PA, QL (typically 28 or 30 tablets/packs), SP.
    • PA documentation should include genotype, fibrosis staging, and prior treatment history when relevant.
    Denial Risk

    NM annotation may indicate denial risk

    Some vaccine and biological entries include NM annotations for certain formulations or age indications; NM may result in denial when billed for non‑covered uses. Verify indication and member eligibility prior to claim submission.

    • Example: certain COMIRNATY entries show AC, NM depending on formulation/age group.
    • Confirm coverage for the specific vaccine formulation and member age; request exception if clinically indicated.
    Prior Authorization

    PA required for many oncology drugs

    PA is required for many oncology drugs listed in the formulary. Claims for these agents may be denied if PA is not obtained. Providers should proactively submit PA requests with full clinical documentation.

    • Numerous oncology agents list PA + QL + SP (examples: ALUNBRIG, AYVAKIT, BOSULIF, IBRANCE, IMBRUVICA).
    • Obtain PA prior to dispensing to avoid denials or member financial liability.
    Prior Authorization

    PA required for MYFEMBREE

    MYFEMBREE requires prior authorization and has a quantity limit of 30 tablets per 30 days. Submit PA with clinical rationale and relevant diagnostic information.

    • MYFEMBREE — PA, QL (30 tablets/30 days).
    Prior Authorization

    PA required for ORIAHNN

    ORIAHNN requires prior authorization and has a quantity limit (56 capsules/28 days). Ensure PA is obtained and the PA submission includes relevant clinical documentation.

    • ORIAHNN — PA, QL (56 capsules/28 days).
    Prior Authorization

    PA required for MOUNJARO

    MOUNJARO (tirzepatide) is annotated with PA and has specific quantity limits depending on formulation: some strengths list QL (4 pens/28 days) or QL (4 pens/180 days) for starter strengths. Obtain PA before dispensing.

    • MOUNJARO — PA, QL (4 pens/28 days for standard strengths; 4 pens/180 days for starter 2.5 mg strength).
    Prior Authorization

    PA required for OZEMPIC

    OZEMPIC (semaglutide) requires prior authorization and has a quantity limit of 1 pen per 28 days. Ensure PA approval prior to dispensing and include indication and prior therapy info as needed.

    • OZEMPIC — PA, QL (1 pen/28 days).
    Denial Risk

    Lack of prior authorization for products listed with 'PA' may trigger coverage denial

    Absence of required prior authorization for products labeled PA may lead to claim denial. Providers should check each drug’s Requirements/Limits and obtain PA prior to dispensing to avoid member liability.

    • Review the Requirements/Limits column for PA and QL notations before prescribing/dispensing.
    • If PA denial occurs, consider step therapy or exception processes as applicable.
    Documentation Required

    Required submission information and documentation to support PA

    Providers must submit PA requests and supporting documentation per the Requirements/Limits listed for each product. Documentation should support dose, indication, prior therapies, and expected duration of therapy to demonstrate medical necessity.

    • Required submission information often includes diagnosis, prior treatment history, lab/pathology/genotype data, and proposed dosing schedule.
    • For expedited clinical situations, an expedited review may be requested (see exception process and contact number on the member ID card).
    Documentation Required

    Document Requirements/Limits

    Drug list entries include coded Requirements/Limits such as PA (prior authorization), QL (quantity limits), SP (specialty), AC (administrative code), BH (behavioral health), ST (step therapy), and NM (not medically necessary). Adhere to the codes listed for each product when submitting requests.

    • Examples of quantity limits: QL 1 pen/28 days, QL 4 pens/28 days, QL 60 tablets/30 days, QL 1200 mls/30 days.
    • Follow submission instructions for the specific Requirement/Limits codes shown.
    Billing Rule

    Quantity limits must be adhered to when submitting

    Some products have explicit quantity limits (QL) which must be respected when submitting PA or when dispensing. If higher quantities are clinically necessary, include justification in the PA request.

    • Examples: QL 1 pen/28 days (OZEMPIC), QL 4 pens/28 days or 4 pens/180 days (MOUNJARO), QL 28 vials/28 days (ARIKAYCE).
    • Requests exceeding QL without approved PA/override may be denied or result in member financial responsibility.
    Documentation Required

    PA documentation note and support for PA requests

    Some PA entries include product‑specific PA documentation notes — for example, liquid formulations, oral solutions, and certain specialty products require PA plus QL and product‑specific documentation (e.g., enalapril oral solution, droxidopa strengths, FUROSCIX). Ensure PA submissions reference the exact formulation and strength.

    • Enalapril oral solution (Epaned) — PA, QL (1200 mL/30 days).
    • FUROSCIX — PA, QL (8 kits/180 days).
    • Droxidopa (Northera) — PA, QL varies by strength (100 mg QL 450 caps/30 days; 200/300 mg QL 180 caps/30 days).
    • REPATHA — PA, QL (6 syringes or 6 pens/28 days).
    Documentation Required

    Submit according to listed Requirements/Limits

    Submit prior authorization requests according to the Requirements/Limits specified on each formulary entry. Include all requested documentation to support medical necessity; specialty products often require SP routing and additional specialty pharmacy forms.

    • Follow the payer’s PA submission process (contact number on member ID card or payer portal).
    • Include indication, prior therapy history, labs/genetic tests, and dosing plan with the PA request.
    Step Therapy

    Step therapy may require trial of first‑line medications

    Step Therapy (ST) programs may require trial of first‑line medications before certain agents are covered. For products carrying an ST flag, prescribers can request a step therapy exception with supporting clinical rationale. Not all segments list ST; where ST applies it will be indicated in the Requirements/Limits column.

    • Example BH/ST entries: FETZIMA, FLUOXETINE DR, FANAPT titration packs show BH and ST flags.
    • Some oncology or specialty agents imply step sequences though explicit ST may not be listed in every segment.
    Note

    Step therapy absence note

    Step therapy is not specified for all listed products in this segment — many entries focus on PA, QL, SP, NM and BH flags. Where ST is not shown, step therapy requirements may not apply.

    • Absence of an ST flag in the Requirements/Limits column generally indicates no step therapy requirement is specified in this segment.
    • If in doubt, contact the payer or call the number on the member’s ID card for confirmation.
    Prior Authorization

    Some agents are marked SP (specialty) or require specialty pharmacy dispensing

    Some agents are specifically designated SP (specialty). Specialty designation often requires specialty pharmacy dispensing, specific PA workflows, and adherence to QL and handling requirements.

    • SP‑flagged products include many oncology agents, biologics, and specialty injectables (examples throughout this formulary).
    • Specialty pharmacies may manage distribution, prior authorizations, and patient support programs.
    Note

    Providers or members can request Drug List or step therapy exceptions by calling the number on the ID card

    Where coverage decisions are needed (exceptions, step therapy or PA), providers or members can request reviews by calling the number on the member’s ID card. Expedited review is available for urgent clinical needs.

    • Standard PA/exception decisions: notice within three business days after receipt of the request.
    • Expedited requests for urgent conditions: decision within 24 hours after receipt.
    Documentation Required

    Behavioral health medication controls

    Behavioral health (BH) medications carry BH program controls and in some cases PA, QL or ST requirements. Failure to comply with BH program authorization may result in denial.

    • Examples: many antidepressants, antipsychotics, and BH agents are flagged BH and may include QL and ST.
    • Follow BH program submission pathways and include relevant clinical history in PA/BH requests.
    Denial Risk

    Denial triggers: missing PA or QL exceedance

    Denial Triggers — Claims may be denied if required prior authorization is missing, if the dispensed quantity exceeds the specified Quantity Limit (QL), or if the drug is billed for an indication marked NM without an approved exception. Providers should verify PA/QL/NM status before dispensing.

    • Missing PA for PA‑flagged products can lead to denial.
    • Exceeding QL without an approved override may result in denial or full member financial responsibility.
    • Drugs marked NM for the billed indication may be denied absent an approved exception.

    Definitions and Code Flags

    Specialty drugs — definition
    DefinitionSpecialty drugs: medications used for serious conditions that may be oral, topical, or injectable and may require special handling or support services.
    Use casesTreat complex conditions such as hepatitis, hemophilia, multiple sclerosis, and rheumatoid arthritis.
    Dispensing noteSome specialty drugs require specialty pharmacy (SP) dispensing or administration by a health care professional and may be routed through the medical benefit.
    Generic types
    Generic equivalentSame active ingredient(s) at the same dosage as the reference brand (chemically the same).
    Generic alternativeDifferent active ingredient used to treat the same condition (not chemically identical to brand).
    Member cost implicationMembers may pay lower cost for generics; choosing brand over available generic may increase member cost-share.
    PA — Prior Authorization
    PA meaningPrior Authorization — approval required before coverage; listed as 'PA' in Requirements/Limits.
    When appliedMany specialty, oncology, and selected branded agents include 'PA' and require prescriber submission of prior authorization documentation.
    Denial riskClaims may be denied if PA is required but not obtained.
    QL — Quantity Limit
    QL meaningQuantity Limit — maximum quantity and time window specified in Requirements/Limits (e.g., 30 tablets/30 days).
    PurposeDispensing limits encourage FDA‑intended use and limit covered quantity per prescription or time period.
    ExamplesShown next to products as 'QL (e.g., 60 tablets/30 days; 1 pen/28 days; 100 mls/30 days)'.
    SP — Specialty Pharmacy
    SP meaningSpecialty Pharmacy — may require dispensing through specialty pharmacy channel and is annotated 'SP' on the Drug List.
    When usedApplied to many injectables, specialty oral therapies, and high‑cost biologics (e.g., Palforzia, many oncology agents).
    ImplicationSpecialty products often require specialty workflow, PA, and adherence to QL; may have limited distribution routing.
    NM — Not Medically Necessary (annotation)
    NM flag'NM' (Not Medically Necessary) appears as a Requirements/Limits annotation for certain formulations and may indicate exclusion for specified indications.
    ExamplesSome azithromycin formulations and selected vaccines are annotated 'NM' in the list.
    EffectEntries marked NM can trigger denial for non‑covered indications if documentation does not support medical necessity.
    AC — Administrative Condition / Authorization Code
    AC meaningAC — Administrative Condition / Authorization Code noted in Requirements/Limits (operational details handled by payer).
    Common useUsed on contraceptive and vaccine lines to indicate administrative conditions or special billing requirements.
    Provider actionFollow listed Requirements/Limits codes and include supporting documentation per payer PA procedures when AC is annotated.
    NM — vaccine annotation (context)
    NM on vaccines'NM' is annotated alongside some vaccines (e.g., COMIRNATY lines) indicating Not Medically Necessary in certain contexts.
    Provider implicationBilling for non‑covered indications may result in denial when NM is present.
    DocumentationProviders should verify indication and follow Requirements/Limits when NM is annotated.
    PA prevalence and implications
    PA prevalencePrior authorization (PA) is widely used for oncology and many specialty agents in this formulary segment.
    Action requiredProviders must obtain PA prior to dispensing when 'PA' is listed to avoid claim denial.
    ExamplesMultiple antineoplastics and specialty drugs in the list show 'PA' with associated QL and SP flags.
    QL — definition and use
    QL annotationQuantity Limit (QL) indicates the allowed maximum quantity per specified time period (e.g., 'QL (60 tablets/30 days)').
    Where shownQLs appear alongside many products including antimicrobials, oncology agents, and specialty therapies.
    Provider noteAdhere to the QL shown on the line item when submitting claims or PA requests.
    SP — Specialty product designation
    SP designation'SP' marks products routed through specialty pharmacy services; often combined with PA and QL annotations.
    ExamplesPalforzia, many oncology and biologic agents are labeled SP in the list.
    Operational impactSpecialty products may require specific dispensing channels and documentation for coverage.

    Initial Dispensing and Therapy Criteria

    Initial dispensing limits

    Quantity limits and prior authorization requirements for initial dispensing where specified.

    Initial dispensing examples: Examples of initial dispensing controls include: ANNOVERA — AC, QL (1 ring/365 days); Vivelle-Dot/Divigel — QL (30 patches/30 days); many contraceptives and topical/patch products list AC and specific QL values.

    Prescribers must request quantities consistent with QL and obtain PA when indicated.

    Initial therapy limits

    Initial therapy limits: Initial fills are subject to the quantity limits listed (e.g., 1 pen/28 days for some injectable pens, 30–60 tablets per 30–180 days depending on product) and prior authorization where indicated; maintenance supplies may be limited to typical 30-day or plan-defined 90-day supplies.

    See product line for exact QL/PA.

    Initial therapy flags

    Examples of products requiring prior authorization and specialty handling.

    Initial therapy flags: Selected specialty biologics and growth hormone products are listed with 'PA' and 'SP' (e.g., GENOTROPIN: Requirements/Limits = PA, SP), indicating prior authorization and specialty pharmacy requirements for initiation.

    Prior authorization documentation and specialty pharmacy routing required per plan.

    Step Therapy / Fail-First Rules

    Step therapy summaryNotes / provider actions
    Step therapy (ST) is identified on the Drug List with an 'ST' notation when a plan-level step requirement applies.Providers or members may request a step therapy exception by calling the number on the member ID card; BCBSNM will notify the requester of a decision within three business days, or within 24 hours for expedited requests when clinically urgent.
    Observed entryStep therapy details present?
    Multiple drug lines in the antiviral/antiretroviral sections (e.g., EPCLUSA, GENVOYA) and various systemic agents shown in these chunks.No explicit multi-step sequences or fail‑first algorithms are listed in these chunks; entries show per-product flags (PA, QL, SP, NM) only.
    ProductStep/pack implication
    Palforzia (LEVEL 0–LEVEL 11 dosing packs)Each level/pack is annotated SP and listed as LEVEL 0–11 packaging; specialty designation and levelized packs imply adherence to packaging/step dosing levels for therapy initiation and maintenance.
    Chunk / product groupStep therapy specified?
    Corticosteroids and related generics (examples shown in chunk)No step therapy entries appear in this excerpt; step therapy not specified for the listed products in these chunks.
    ProductStep therapy specified?
    MOUNJARO (tirzepatide) and other antidiabetic GLP-1/GIP agents (examples: MOUNJARO, OZEMPIC)No explicit step‑therapy sequences are provided here; entries list PA and QL but not step therapy algorithms in these chunks.
    Products notedAuthorization requirement
    Selected high-cost agents and GLP‑1/GIP products (examples listed: MOUNJARO, OZEMPIC, ACTHAR, CRENESSITY)These products are annotated with 'PA' (prior authorization) in the Requirements/Limits field — prior authorization is required before coverage is approved.
    ProductPlan flag
    KERENDIAFlagged with 'ST' in the formulary indicating a step therapy requirement applies per the plan.
    ProductsAuthorization / step therapy
    NEXLETOL (bempedoic acid) / NEXLIZET (bempedoic acid-ezetimibe)Both entries show 'PA' and 'QL (30 tablets/30 days)'; no explicit step-therapy sequence is described in these chunks.
    Chunk / product examplesStep therapy status
    Various antiviral, vaccine, and generic product lines shown across these segmentsNo explicit step therapy requirements appear in these segments; other parts of the full document may contain step edits not present here.
    Products with ST flagImplication
    Examples: FETZIMA titration pack, FLUOXETINE DR, FANAPT (and titration packs), CLOZAPINE ODT, TRINTELLIX (examples from BH/antidepressant sections)Where 'ST' is indicated alongside these products (often with BH designation), step therapy requirements apply — prior trials of preferred agents or behavioral‑health program rules may be required per plan.
    Chunk / product groupStep therapy details present?
    Neurology / multiple neurologic and BH product listings (examples: dimethyl fumarate, fingolimod, glatiramer acetate) and other specialty linesStep therapy specifics are not included in these chunks; listed requirements focus on PA, QL, SP and BH flags rather than explicit step algorithms.

    Quantity Limits and Maintenance Supply Guidance

    Site-of-Care and Specialty Pharmacy

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Background

    Specialty drugs are used to treat complex, often chronic conditions (for example, hepatitis, hemophilia, multiple sclerosis, and rheumatoid arthritis). They may be self‑administered (e.g., auto‑injector or pen) or administered in a health‑care setting; medications requiring provider administration may be billed to the medical benefit rather than the pharmacy benefit. The formulary classifies medications by therapeutic class and by FDA‑approved primary indication and includes utilization controls (PA, QL, SP) on many specialty products.